丙酮酸激酶M2在肝癌发病及诊疗中的作用

次旦旺久; 赵相轩; 王晓明

doi:10.3969/j.issn.1001-5256.2016.04.046

丙酮酸激酶M2在肝癌发病及诊疗中的作用

DOI: 10.3969/j.issn.1001-5256.2016.04.046

中国医科大学附属盛京医院放射科

基金项目:

国家自然科学基金资助项目(81471720);国家自然科学基金面上项目(31371425)；辽宁省自然科学基金(2013023056)；盛京医院自由者研究项目(200802)；盛京自由研究者基金(200802)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2152
- HTML全文浏览量: 17
- PDF下载量: 444
- 被引次数: 0
出版历程
- 出版日期: 2016-04-20

Role of pyruvate kinase muscle isozyme 2 in pathogenesis and diagnosis of liver cancer

Department of Radiology, Shengjing Hospital of China Medical University

Research funding:

摘要

摘要:
近几年研究发现,丙酮酸激酶(PK)M2在多种肿瘤组织细胞中表达显著增加,在肿瘤细胞内起到信号分子的作用,参与肿瘤细胞增殖相关基因的表达、调控、细胞自噬以及细胞周期进程等过程。总结了PKM2在肝癌组织及肝癌细胞系中的表达情况,分别阐述了PKM2在肝癌细胞增殖、分化、转移以及临床预后评价中的作用,认为其在肝癌临床诊断、治疗以及预后评价中具有潜在价值。
- 丙酮酸激酶 /
- 肝肿瘤 /
- 综述
Abstract:
In recent years,studies have shown that the expression of pyruvate kinase muscle isozyme 2( PKM2) is increased significantly in various tumor cells. PKM2 acts like a signal molecule in tumor cells and participates in the expression and regulation of genes related to tumor cell proliferation,cell autophagy,and cell cycle progression. This article summarizes the expression of PKM2 in liver cancer tissues and cell lines,elaborates on the role of PKM2 in the proliferation,differentiation,and metastasis of liver cancer cells and prognostic evaluation,and points out that PKM2 can be used in the clinical diagnosis,treatment,and prognostic evaluation of liver cancer.
- pyruvate kinase /
- liver neoplasms /
- review

HTML全文

参考文献(50)

[1]FILIPP FV.Cancer metabolism meets systems biology:pyruvate kinase isoform PKM2 is a metabolic master regulator[J].J Carcinog,2013,12(1):14.

[2]CHANETON B,GOTTLIEB E.Rocking cell metabolism:revised functions of the key glycolytic regulator PKM2 in cancer[J].Trends Biochem Sci,2012,37(8):309-316.

[3]MAZUREK S.Pyruvate kinase type M2:a key regulator of the metabolic budget system in tumor cells[J].Int J Biochem Cell Biol,2011,43(7):969-980.

[4] LV L,XU YP,ZHAO D,et al.Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization[J].Mol Cell,2013,52(3):340-352.

[5]CHIAVARINA B,WHITAKER-MENEZES D,MARTINEZ-OUT-SCHOORN UE,et al.Pyruvate kinase expression(PKM1 and PKM2)in cancer-associated fibroblasts drives stromal nutrient production and tumor growth[J].Cancer Biol Ther,2011,12(12):1101-1113.

[6]LEE J,KIM H K,HAN Y M,et al.Pyruvate kinase isozyme type M2(PKM2)interacts and cooperates with Oct-4 in regulating transcription[J].Int J Biochem Cell Biol,2008,40(5):1043-1054.

[7]PRIGIONE A,ROHWER N,HOFFMANN S,et al.HIF1alpha modulates cell fate reprogramming through early glycolytic shift and upregulation of PDK1-3 and PKM2[J].Stem Cells,2014,32(2):364-376.

[8]YANG W,XIA Y,JI H,et al.Nuclear PKM2 regulates betacatenin transactivation upon EGFR activation[J].Nature,2011,480(7375):118-122.

[9]YANG W,XIA Y,HAWKE D,et al.PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis[J].Cell,2012,150(4):685-696.

[10]GAO X,WANG H,YANG JJ,et al.Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase[J].Mol Cell,2012,45(5):598-609.

[11]LV L,XU YP,ZHAO D,et al.Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization[J].Mol Cell,2013,52(3):340-352.

[12]LO CH,FARINA F,MORRIS HP,et al.Glycolytic regulation in rat liver and hepatomas[J].Adv Enzyme Regul,1968,6:453-464.

[13]XU Q,LIU X,ZHENG X,et al.PKM2 regulates Gli1 expression in hepatocellular carcinoma[J].Oncol Lett,2014,8(5):1973-1979.

[14]CHRISTOFK HR,VANDER HEIDEN MG,HARRIS MH,et al.The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth[J].Nature,2008,452(7184):230-233.

[15]TAMADA M,SUEMATSU M,SAYA H.Pyruvate kinase M2:multiple faces for conferring benefits on cancer cells[J].Clin Cancer Res,2012,18(20):5554-5561.

[16]LUO W,SEMENZA GL.Emerging roles of PKM2 in cell metabolism and cancer progression[J].Trends Endocrinol Metab,2012,23(11):560-566.

[17]BLUEMLEIN K,GRUNING NM,FEICHTINGER RG,et al.No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis[J].Oncotarget,2011,2(5):393-400.

[18] VANDER HEIDEN MG,CANTLEY LC,THOMPSON CB.Understanding the warburg effect:the metabolic requirements of cell proliferation[J].Science(NY),2009,324(5930):1029-1033.

[19]HITOSUGI T,KANG S,VANDER HEIDEN MG,et al.Tyrosine phosphorylation inhibits PKM2 to promote the warburg effect and tumor growth[J].Sci Signal,2009,2(97):ra73.

[20]GAO X,WANG H,YANG JJ,et al.Reciprocal regulation of protein kinase and pyruvate kinase activities of pyruvate kinase M2 by growth signals[J].J Biol Chem,2013,288(22):15971-15979.

[21]ASHIZAWA K,WILLINGHAM MC,LIANG CM,et al.In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated via fructose 1,6-bisphosphate[J].J Biol Chem,1991,266(25):16842-16846.

[22]ASHIZAWA K,MCPHIE P,LIN KH,et al.An in vitro novel mechanism of regulating the activity of pyruvate kinase M2 by thyroid hormone and fructose 1,6-bisphosphate[J].Biochemistry,1991,30(29):7105-7111.

[23]LV L,LI D,ZHAO D,et al.Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth[J].Mol Cell,2011,42(6):719-730.

[24]ANASTASIOU D,POULOGIANNIS G,ASARA JM,et al.Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses[J].Science(NY),2011,334(6060):1278-1283.

[25]KEFAS B,COMEAU L,ERDLE N,et al.Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells[J].Neuro Oncol,2010,12(11):1102-1112.

[26]ZHANG LF,LOU JT,LU MH,et al.Suppression of miR-199a maturation by HuR is crucial for hypoxia-induced glycolytic switch in hepatocellular carcinoma[J].EMBO J,2015,34(21):2671-2685.

[27]KOSUGI M,AHMAD R,ALAM M,et al.MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells[J].PLoS One,2011,6(11):e28234.

[28]SHIMADA N,SHINAGAWA T,ISHII S.Modulation of M2-type pyruvate kinase activity by the cytoplasmic PML tumor suppressor protein[J].Genes Cells,2008,13(3):245-254.

[29]GUMINSKA M,STACHURSKA MB,IGNACAK J.Pyruvate kinase isoenzymes in chromatin extracts of Ehrlich ascites tumour,Morris hepatoma 7777 and normal mouse and rat livers[J].Biochim Biophys Acta,1988,966(2):207-213.

[30]DONG T,YAN Y,CHAI H,et al.Pyruvate kinase M2 affects liver cancer cell behavior through up-regulation of HIF-1alpha and Bcl-xL in culture[J].Biomed Pharmacother,2015,69:277-284.

[31]HU W,LU SX,LI M,et al.Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma[J].Oncotarget,2015,6(9):6570-6583.

[32]CHEN Z,LU X,WANG Z,et al.Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma[J].Oncotarget,2015,6(4):2538-2548.

[33]LIU WR,TIAN MX,YANG LX,et al.PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma[J].Oncotarget,2015,6(2):846-861.

[34]CHEN SH,SHI WM,CHEN HL,et al.Further study on the value of M2-type pyvarate type kinase in the diagnosis of primary hepatocarcinoma[J].Chin J Oncol,1993,15(4):268-270.(in Chinese)陈士浩,施伟民,陈慧黎,等.M2型丙酮酸激酶对肝癌诊断意义的进一步研究[J].中华肿瘤杂志,1993,15(4):268-270.

[35]WANG C,DELOGU S,HO C,et al.Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways[J].J Hepatol,2012,57(3):577-583.

[36]LUO W,HU H,CHANG R,et al.Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1[J].Cell,2011,145(5):732-744.

[37]KITAMURA K,HATANO E,HIGASHI T,et al.Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis[J].J Hepatol,2011,55(4):846-857.

[38]TANAKA M,MASAKI Y,TANAKA K,et al.Reduction of fatty acid oxidation and responses to hypoxia correlate with the progression of de-differentiation in HCC[J].Mol Med Report,2013,7(2):365-570.

[39]SHEN YN,LU JH.Molecular targeted therapy for hepatocellular carcinoma[J].J Clin Hepatol,2015,31(1):130-134.(in Chinese)沈艺南,卢军华.肝细胞癌相关分子靶向治疗研究进展[J].临床肝胆病杂志,2015,31(1):130-134.

[40]FAN FT,SHEN CS,TAO L,et al.PKM2 regulates hepatocellular carcinoma cell epithelial-mesenchymal transition and migration upon EGFR activation[J].Asian Pac J Cancer Prev,2014,15(5):1961-1970.

[41]WONG CC,AU SL,TSE AP,et al.Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis[J].PLoS One,2014,9(12):e115036.

[42]ZHANG X,HE C,HE C,et al.Nuclear PKM2 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma[J].Pathol Res Pract,2013,209(8):510-515.

[43]LIM JY,YOON SO,SEOL SY,et al.Overexpression of the M2isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer[J].World J Gastroenterol,2012,18(30):4037-4043.

[44]WONG N,YAN J,OJO D,et al.Changes in PKM2 associate with prostate cancer progression[J].Cancer Invest,2014,32(7):330-338.

[45]TONUS C,SELLINGER M,KOSS K,et al.Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening:a meta-analysis[J].World J Gastroenterol,2012,18(30):4004-4011.

[46]MENG W,ZHU HH,XU ZF,et al.Serum M2-pyruvate kianse:a promising non-invasive biomarker for colorectal cancer mass screening[J].World J Gastroenterol,2012,4(6):145-151.

[47]GOLDBERG MS,SHARP PA.Pyruvate kinase M2-specific siR-NA induces apoptosis and tumor regression[J].J Exp Med,2012,209(2):217-224.

[48]YANG W,XIA Y,CAO Y,et al.EGFR-induced and PKCepsilon monoubiquitylation-dependent NF-kappaB activation upregulates PKM2 expression and promotes tumorigenesis[J].Molecular cell,2012,48(5):771-784.

[49]GORRINI C,HARRIS IS,MAK TW.Modulation of oxidative stress as an anticancer strategy[J].Nat Rev Drug Discov,2013,12(12):931-947.

[50]JUNG Y,JANG YJ,KANG MH,et al.Metabolic signature genes associated with susceptibility to pyruvate kinase,muscle type 2 gene ablation in cancer cells[J].Mol Cells,2013,35(4):335-341.

施引文献

资源附件(0)

访问统计